Skye Bioscience (SKYE)Director sold ~$2.5K

~$2.5K

Approx. value · 1,285 sh @ $1.91

5,616

Holds after · shares reported

Traded

Sep 16, 2026

Filed

Sep 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 12, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesControl of the company changed hands, and changed a top executive or board member (and 5 more items)“To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company.”
2. Aug 12, 2026Company filing · Form 8-K · Shareholder rightsChanged the rights of its shareholders
3. Aug 18, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On August 18, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s stockholders’ equity was ($497,307), and therefore, the Company was not in compliance with…”
4. Aug 18, 2026Insider · 2 peopleInsiders: 6 sales (~$228K)
5. Aug 19, 2026Insider · 2 peopleInsiders: 6 sales (~$48K)
6. Aug 20, 2026Insider · 2 peopleInsiders: 6 sales (~$5K)
7. Aug 21, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
8. Sep 8, 2026Company filing · Form 8-K · Agreement ended, Executive changeChanged a top executive or board member, and ended an important agreement (and 1 more item)“On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.”
9. Sep 16, 2026 · this disclosureInsiderDirector sold ~$2.5K of SKYE shares in the open market

What came next

1. Sep 16, 2026Insider · 2 peopleInsiders: 3 sales (~$127K)
2. Sep 22, 2026Insider · 2 peopleInsiders: 4 sales (~$95K)
3. Sep 23, 2026Insider · 2 peopleInsiders: 4 sales (~$384K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Skye Bioscience

For Skye Bioscience, OQRO holds 30 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SKYE page.

Other recent filings by Andrew J. Schwab, Director

• SEC Form 4 at Skye Bioscience (SKYE)Sep 24, 2026
• SEC Form 4 at Skye Bioscience (SKYE)Sep 24, 2026
• SEC Form 4 at Skye Bioscience (SKYE)Sep 24, 2026
• SEC Form 4 at Skye Bioscience (SKYE)Sep 24, 2026
• SEC Form 4 at Skye Bioscience (SKYE)Sep 18, 2026

The full history of Andrew J. Schwab, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Skye Bioscience

• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 24, 2026

Everything OQRO holds on this company is on its SKYE page.